Has Melissa Manriques received payments from drug or device companies?

Yes. Drug and device makers reported $3,587 in general payments to Melissa Manriques across 88 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Melissa Manriques did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Melissa Manriques come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Melissa Manriques

Primary Care · Fresno, CANPI 1679564140

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.6% of the total across 88 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Incyte Corporation at 25.7% of the total. Among primary care clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,587in general payments, 2019–2025

Across 88 payments — averaging $40.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Incyte Corporation$921
AbbVie$566
Pfizer$469
LEO Pharma Inc.$288
Galderma Laboratories, L.p.$275
E.r. Squibb & Sons, L.L.C.$250
plus $819 from 9 others

What the payments were for

Food & beverage$3,39395%
Education$1945%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Incyte Corporation	21	$921
AbbVie(2 entities)	20	$566
Pfizer	12	$469
LEO Pharma Inc.	4	$288
Galderma Laboratories, L.p.	8	$275
E.r. Squibb & Sons, L.L.C.	2	$250
Regeneron Healthcare Solutions, Inc.	2	$150
Ortho Dermatologics, A Division Of Bausch Health US, LLC	2	$141
Arcutis Biotherapeutics, Inc.	2	$139
Johnson & Johnson	3	$138
Sanofi	3	$91
Biofrontera Inc.	5	$60
Lilly USA, LLC	2	$47
Novartis	1	$34
Revance Therapeutics, Inc.	1	$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

OPZELURA$577
Sotyktu$250
Skyrizi$125
ZORYVE$125
BOTOX$121
CIBINQO$106
ADBRY$104
NEMLUVIO$103
DUPIXENT$102

How this compares

$3,587 in reported general payments places this provider in the 90th percentile of 706 primary care providers in California.

See all primary care providers in California →

Medicare billing

Part B allowed, 2024

$107,951

Medicare patients

383

Services billed

3,015

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dupixent PenDupilumab	45	$160,107
Humira(Cf) PenAdalimumab	13	$90,734
Clobetasol Propionate	57	$2,399
Ketoconazole	92	$2,047
Metronidazole	18	$1,236
Triamcinolone Acetonide	97	$1,064
Betamethasone Dipropionate	31	$993
Fluorouracil	13	$913
Doxycycline Hyclate	49	$577
ValacyclovirValacyclovir Hcl	13	$412
Clindamycin Phosphate	11	$369
Mupirocin	19	$113
Hydrocortisone	23	$88

Paid to pharmacies, not to this prescriber.

Other primary care in Fresno

Brittney StanleyFresno$14K
Sherri NashFresno$9K
Phaxi YangFresno$8K
Michelle BergenFresno$4K
Joan NunooFresno$4K
Leslie FletcherTorrance$1.8M
Hamideh PourzandLos Angeles$103K
Veronica RamirezSacramento$83K
Tyson FieldstedBakersfield$65K
Kathryn CooperSan Diego$31K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →